Press Releases Sutro Biopharma, Inc.

Equities

STRO

US8693671021

Market Closed - Nasdaq Other stock markets 01:30:00 03/05/2024 am IST			5-day change	1st Jan Change
3.94 ^USD	+5.35%		+15.20%	-8.16%

30/04	Sutro Biopharma, Inc. Announces Initiation of Randomized Portion (Part 2) of REFRaME-O1 Trial	CI
03/04	Piper Sandler Trims Price Target on Sutro Biopharma to $11 From $12, Maintains Overweight Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial	30/04	AQ
Sutro Biopharma : Bill Newell, CEO Interviewed by Brad Loncar, Founder, Biotech TV – “Sutro Biopharma’s CEO on ADCs, non-cell protein synthesis, and more”	05/04	PU
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering	02/04	AQ
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones	26/03	AQ
Sutro Biopharma to Participate in Upcoming Investor Conferences	07/02	AQ
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC	05/01	AQ
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolR-targeted ADC, on January 4, 2024	15/12	AQ
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024	15/12	AQ
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin in Pediatric Patients with Relapsed, Refractory CBF/GLIS Presented at ASH 2023	12/12	AQ
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023	12/12	AQ
Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit	05/12	AQ
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates	28/11	AQ
Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer	22/11	AQ
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones	14/11	AQ
Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023	23/23/23	AQ
Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023	22/23/22	AQ
Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference	17/23/17	AQ
Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer	19/23/19	AQ
Sutro Biopharma to Participate in Upcoming Investor Conferences	30/23/30	AQ
Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones	11/23/11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Sutro Biopharma, Inc.

Equities

STRO

US8693671021

Press Releases

Filters